PT-141 (bremelanotide) is FDA-approved for premenopausal women with hypoactive sexual desire disorder.
Human testing subjects reported unexpected sexual arousal. Palatin Technologies developed PT-141 because of that.
| Detail | |
|---|---|
| Also called | Bremelanotide, Vyleesi |
| Sequence | Ac-Nle-cyclo-(Asp-His-D-Phe-Arg-Trp-Lys)-OH |
| Molecular weight | ~1025.2 |
| CAS | 189691-06-3 (free base) |
| Half-life | ~2.7 hours |
| Approved dose | 1.75 mg subcutaneous, as needed |
How It Works
This is the part that actually matters, and it separates PT-141 from every other option on the market. The two drug classes act on completely different systems.
- Activates melanocortin receptors (MC4R and MC1R)
- Signals the hypothalamus and medial preoptic area
- Engages dopamine pathways tied to sexual motivation
- Result: acts on desire itself
- Blocks the PDE-5 enzyme in vessel walls
- Smooth muscle relaxes, vessels widen
- Blood flow to tissue increases
- Result: enables physical response
PDE-5 inhibitors amplify a response that has already started. If interest is not there, they have nothing to work with. PT-141 targets the signal upstream, which is why studies found responses in some men who did not respond to PDE-5 inhibitors at all.
One honest caveat, straight from the FDA label: the exact mechanism by which bremelanotide improves HSDD is listed as unknown. The pathway above is well supported in animal research, but it remains a model rather than settled fact.
What Scientist Found
Two Phase 3 trials with 1,247 premenopausal women with HSDD over 24 weeks. Published in Obstetrics & Gynecology in 2019.
| Outcome | Result |
| Desire score (FSFI-D) | Improved vs placebo, p<0.001 |
| Distress score | Improved vs placebo, p<0.001 |
| Effect size (Cohen’s d) | 0.39 desire, 0.27 distress (small) |
| Responder rate | ~58% vs ~35% placebo |
| Satisfying sexual events | No significant difference (p=0.76, 0.70) |
| Dropout from side effects | 18% vs 2% placebo |
It beat placebo for women who rated desire and distress. Not more sexual satisfaction than placebo.
The effect sizes are small by convention (0.2 small, 0.5 medium, 0.8 large). Placebo response was high at around 35%.
The Journal of Sex Research says most protocol-listed outcomes went unreported. Basically, it showed only modest benefits for women with low sexual desire.
More importantly, women were much more likely to quit because of side effects. And also less likely to choose it over placebo. In other words, the drug may not be very useful. The original researchers selectively presented the evidence.
PT-141 offers real but modest average desire effects. The “female Viagra” is an overstatement of the mechanism and the scope of the effect.
Side Effects
From the FDA label:
| Effect | Rate | Placebo |
|---|---|---|
| Nausea | 40.0% | 1.3% |
| Flushing | 20.3% | 0.3% |
| Injection site reactions | 13.2% | 8.4% |
| Headache | 11.3% | 1.9% |
| Vomiting | 4.8% | — |
Nausea dominates. Reported by 21% after the first dose. Drops to around 3% after later doses. 13% needed an anti-emetic. 8% quit because of it.
Cardiovascular: blood pressure briefly rises and heart rate drops after each dose.
Pigmentation: focal hyperpigmentation occurred in 1% at the approved frequency. With daily dosing, 38% developed it within 8 days. Risk is higher with darker skin, and it did not resolve in every patient after stopping.
Who Should Not Use It
This is not a section people should ignore or take for granted.
- Uncontrolled high blood pressure or known cardiovascular disease
- Anyone taking oral naltrexone
- Pregnancy (Animal data showed fetal harm)
- Anyone on oral medications needing fast onset or threshold concentrations
Cap use one dose per 24 hours and eight per month. Frequent use increases hyperpigmentation risk and extends time spent with elevated blood pressure.
PT-141 vs Viagra and Cialis
| PT-141 | PDE-5 inhibitors | |
|---|---|---|
| Target | Brain (melanocortin receptors) | Blood vessels |
| Addresses | Desire | Physical response |
| Onset | ~45 min per label, variable in practice | 30 to 60 min |
| Evidence in men | Off-label, older studies | Large, established |
| Main side effect | Nausea (40%) | Headache, flushing |
The Two Ways People Get It
| Vyleesi (prescription) | Research vials | |
|---|---|---|
| FDA approved | Yes | No |
| Quality controlled | Yes | Vendor-dependent |
| Who it is approved for | Premenopausal women with HSDD | Nobody, laboratory use only |
| Medical screening | Yes | None |
| Cost | High list price, but manufacturer programs can drop a 4-injection box to $0 insured or $99 uninsured | ~$35 to $80 per 10mg vial |
Should You Get It From Peptide Vendors?
Purity is the minimum. A real certificate of analysis with a real HPLC chromatogram. Mass spectrometry that confirms the ~1025 Da cyclic peptide. A lot number matching the vial.
Trusted third-party labs are much more important than vendor’s claims.
The peptide vendor verification guide points you in the right direction.
Is PT-141 the same as Vyleesi?
Same molecule, bremelanotide. Vyleesi is the approved, quality-controlled prescription product. “PT-141” sold online is unapproved research-grade material.
Does PT-141 work?
In the pivotal trials it improved self-reported desire and distress with small effect sizes, but did not increase satisfying sexual events versus placebo.
How long does it take to work?
The label directs dosing at least 45 minutes before activity. The label also states the duration of effect after each dose is unknown.
Does PT-141 work for men?
There is no FDA-approved indication for men. Older studies suggested erectile responses including in some PDE-5 non-responders, but this remains off-label.
PT-141 vs Melanotan 2?
Same research origin. Melanotan 2 activates melanocortin receptors non-selectively, producing stronger pigmentation and a broader side effect profile. PT-141 was developed to be more targeted.
Conclusion
PT-141 is approved. Has real trials and can be bought legally with a prescription.
It has shown small improvement for desire and distress. No measurable increase in satisfaction. 1 in 5 people quit because of side effects, with nausea being the main one.
Check over the side effects again and take them seriously.
Educational content only, not medical advice. PT-141 sold as “research use only” is not approved for human use. Vyleesi is a prescription medication approved for a specific, narrow indication. Sexual dysfunction has many causes, some of them medical, and evaluation by a qualified clinician is the appropriate first step. Consult a doctor before considering any treatment discussed here. Some links may be affiliate links.